| Year |
Citation |
Score |
| 2023 |
Eskander RN, Moore KN, Monk BJ, Herzog TJ, Annunziata CM, O'Malley DM, Coleman RL. Overcoming the challenges of drug development in platinum-resistant ovarian cancer. Frontiers in Oncology. 13: 1258228. PMID 37916177 DOI: 10.3389/fonc.2023.1258228 |
0.304 |
|
| 2023 |
Harrington BS, Kamdar R, Ning F, Korrapati S, Caminear MW, Hernandez LF, Butcher D, Edmondson EF, Traficante N, Hendley J, Gough M, Rogers R, Lourie R, Shetty J, Tran B, ... ... Annunziata CM, et al. UGDH promotes tumor-initiating cells and a fibroinflammatory tumor microenvironment in ovarian cancer. Journal of Experimental & Clinical Cancer Research : Cr. 42: 270. PMID 37858159 DOI: 10.1186/s13046-023-02820-z |
0.302 |
|
| 2023 |
Shibuya Y, Kudo K, Zeligs KP, Anderson D, Hernandez L, Ning F, Cole CB, Fergusson M, Kedei N, Lyons J, Taylor J, Korrapati S, Annunziata CM. SMAC Mimetics Synergistically Cooperate with HDAC Inhibitors Enhancing TNF-α Autocrine Signaling. Cancers. 15. PMID 36831656 DOI: 10.3390/cancers15041315 |
0.328 |
|
| 2022 |
Tsang KY, Fantini M, Mavroukakis SA, Zaki A, Annunziata CM, Arlen PM. Development and Characterization of an Anti-Cancer Monoclonal Antibody for Treatment of Human Carcinomas. Cancers. 14. PMID 35804808 DOI: 10.3390/cancers14133037 |
0.34 |
|
| 2022 |
Caminear MW, Harrington BS, Kamdar RD, Kruhlak MJ, Annunziata CM. Disulfiram Transcends ALDH Inhibitory Activity When Targeting Ovarian Cancer Tumor-Initiating Cells. Frontiers in Oncology. 12: 762820. PMID 35372040 DOI: 10.3389/fonc.2022.762820 |
0.366 |
|
| 2021 |
Hernandez LF, Dull AB, Korrapati S, Annunziata CM. Smac-mimetic enhances antitumor effect of standard chemotherapy in ovarian cancer models via Caspase 8-independent mechanism. Cell Death Discovery. 7: 134. PMID 34088893 DOI: 10.1038/s41420-021-00511-2 |
0.334 |
|
| 2020 |
Ning F, Cole CB, Annunziata CM. Driving Immune Responses in the Ovarian Tumor Microenvironment. Frontiers in Oncology. 10: 604084. PMID 33520713 DOI: 10.3389/fonc.2020.604084 |
0.311 |
|
| 2020 |
Walcott FL, Wang PY, Bryla CM, Huffstutler RD, Singh N, Pollak MN, Khincha PP, Savage SA, Mai PL, Dodd KW, Hwang PM, Fojo AT, Annunziata CM. Pilot Study Assessing Tolerability and Metabolic Effects of Metformin in Patients With Li-Fraumeni Syndrome. Jnci Cancer Spectrum. 4: pkaa063. PMID 33490865 DOI: 10.1093/Jncics/Pkaa063 |
0.331 |
|
| 2020 |
Noonan AM, Cousins A, Anderson D, Zeligs KP, Bunch K, Hernandez L, Shibuya Y, Goldlust IS, Guha R, Ferrer M, Thomas CJ, Annunziata CM. Matrix Drug Screen Identifies Synergistic Drug Combinations to Augment SMAC Mimetic Activity in Ovarian Cancer. Cancers. 12. PMID 33334024 DOI: 10.3390/cancers12123784 |
0.328 |
|
| 2020 |
Lee JM, Annunziata CM, Hays JL, Cao L, Choyke P, Yu M, An D, Turkbey IB, Minasian LM, Steinberg SM, Chen H, Wright J, Kohn EC. Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment. Gynecologic Oncology. PMID 32747013 DOI: 10.1016/J.Ygyno.2020.07.031 |
0.418 |
|
| 2020 |
Zeligs KP, Morelli MP, David JM, Neuman M, Hernandez L, Hewitt S, Ozaki M, Osei-Tutu A, Anderson D, Andresson T, Das S, Lack J, Abdelmaksoud A, Fantini M, Arlen PM, ... ... Annunziata CM, et al. Evaluation of the Anti-Tumor Activity of the Humanized Monoclonal Antibody NEO-201 in Preclinical Models of Ovarian Cancer. Frontiers in Oncology. 10: 805. PMID 32637350 DOI: 10.3389/Fonc.2020.00805 |
0.462 |
|
| 2020 |
Harrington BS, Ozaki MK, Caminear MW, Hernandez LF, Jordan E, Kalinowski NJ, Goldlust IS, Guha R, Ferrer M, Thomas C, Shetty J, Tran B, Wong N, House CD, Annunziata CM. Drugs Targeting Tumor-Initiating Cells Prolong Survival in a Post-Surgery, Post-Chemotherapy Ovarian Cancer Relapse Model. Cancers. 12. PMID 32575908 DOI: 10.3390/Cancers12061645 |
0.397 |
|
| 2020 |
Lampert EJ, Zimmer AS, Padget MR, Cimino-Mathews A, Nair JR, Liu Y, Swisher EM, Hodge JW, Nixon AB, Nichols E, Bagheri M, Levy E, Radke MR, Lipkowitz S, Annunziata CM, et al. Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32398324 DOI: 10.1158/1078-0432.Ccr-20-0056 |
0.357 |
|
| 2020 |
Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, Kohn EC, Levine DA, Liu JF, Lu KH, Sparacio D, Annunziata CM. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1902960. PMID 31986064 DOI: 10.1200/Jco.19.02960 |
0.38 |
|
| 2020 |
Fantini M, David JM, Annunziata CM, Morelli MP, Arlen PM, Tsang KY. The Monoclonal Antibody NEO-201 Enhances Natural Killer Cell Cytotoxicity Against Tumor Cells Through Blockade of the Inhibitory CEACAM5/CEACAM1 Immune Checkpoint Pathway. Cancer Biotherapy & Radiopharmaceuticals. PMID 31928422 DOI: 10.1089/Cbr.2019.3141 |
0.384 |
|
| 2020 |
Annunziata CM, Duemler A, Ning F. Interferons alpha and gamma with monocytes as a therapeutic strategy for ovarian cancer. Journal of Clinical Oncology. 38: 9-9. DOI: 10.1200/Jco.2020.38.5_Suppl.9 |
0.323 |
|
| 2020 |
Cole CB, Annunziata CM. First-in-human phase I study of intraperitoneally administered interferon-activated autologous monocytes in platinum-resistant or refractory ovarian cancer. Journal of Clinical Oncology. 38: 1-1. DOI: 10.1200/Jco.2020.38.5_Suppl.1 |
0.354 |
|
| 2020 |
Morelli MP, Fantini M, Houston ND, Lee J, Zimmer ADS, Lipkowitz S, Trewhitt K, Arlen PM, Tsang KY, Annunziata CM. Correlation of clinical activity of NEO201 mAb with the expression of NK activation markers and levels of soluble factors. Journal of Clinical Oncology. 38: e15002-e15002. DOI: 10.1200/Jco.2020.38.15_Suppl.E15002 |
0.382 |
|
| 2020 |
Lampert EJ, An D, McCoy A, Kohn EC, Annunziata CM, Trewhitt K, Zimmer ADS, Lipkowitz S, Lee J. Prexasertib, a cell cycle checkpoint kinase 1 inhibitor, in BRCA mutant recurrent high-grade serous ovarian cancer (HGSOC): A proof-of-concept single arm phase II study. Journal of Clinical Oncology. 38: 6038-6038. DOI: 10.1200/Jco.2020.38.15_Suppl.6038 |
0.385 |
|
| 2020 |
Annunziata CM, Ghobadi A, Pennella EJ, Vanas J, Powell C, Pavelova M, Wagner C, Kuo M, Ullmann CD, Hassan R, Thaker PH. Feasibility and preliminary safety and efficacy of first-in-human intraperitoneal delivery of MCY-M11, anti-human-mesothelin CAR mRNA transfected into peripheral blood mononuclear cells, for ovarian cancer and malignant peritoneal mesothelioma. Journal of Clinical Oncology. 38: 3014-3014. DOI: 10.1200/Jco.2020.38.15_Suppl.3014 |
0.344 |
|
| 2020 |
Morelli MP, Fanitni M, Diggs A, Tsang KY, Arlen P, Annunziata C. Abstract 3315: Activating innate immune response as strategy for endometrial cancer treatment Immunology. 80: 3315-3315. DOI: 10.1158/1538-7445.Am2020-3315 |
0.454 |
|
| 2019 |
Lee JM, Botesteanu DA, Tomita Y, Yuno A, Lee MJ, Kohn EC, Annunziata CM, Matulonis U, MacDonald LA, Nair JR, Macneill KM, Trepel JB. Patients with BRCA mutated ovarian cancer may have fewer circulating MDSC and more peripheral CD8 T cells compared with women with BRCA wild-type disease during the early disease course. Oncology Letters. 18: 3914-3924. PMID 31516602 DOI: 10.3892/Ol.2019.10731 |
0.377 |
|
| 2019 |
Harrington BS, Annunziata CM. NF-κB Signaling in Ovarian Cancer. Cancers. 11. PMID 31443240 DOI: 10.3390/Cancers11081182 |
0.429 |
|
| 2019 |
Zimmer AS, Nichols E, Cimino-Mathews A, Peer C, Cao L, Lee MJ, Kohn EC, Annunziata CM, Lipkowitz S, Trepel JB, Sharma R, Mikkilineni L, Gatti-Mays M, Figg WD, Houston ND, et al. A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses. Journal For Immunotherapy of Cancer. 7: 197. PMID 31345267 DOI: 10.1186/S40425-019-0680-3 |
0.338 |
|
| 2019 |
Lampert EJ, Hays JL, Kohn EC, Annunziata CM, Minasian L, Yu M, Gordon N, Sissung TM, Chiou VL, Figg WD, Houston N, Lee JM. Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk. Oncotarget. 10: 2855-2868. PMID 31080557 DOI: 10.18632/Oncotarget.26869 |
0.344 |
|
| 2019 |
Green DS, Nunes AT, Tosh KW, David-Ocampo V, Fellowes VS, Ren J, Jin J, Frodigh SE, Pham C, Procter J, Tran C, Ekwede I, Khuu H, Stroncek DF, Highfill SL, ... ... Annunziata CM, et al. Production of a cellular product consisting of monocytes stimulated with Sylatron (Peginterferon alfa-2b) and Actimmune (Interferon gamma-1b) for human use. Journal of Translational Medicine. 17: 82. PMID 30871636 DOI: 10.1186/S12967-019-1822-6 |
0.37 |
|
| 2019 |
Disis ML, Taylor MH, Kelly K, Beck JT, Gordon M, Moore KM, Patel MR, Chaves J, Park H, Mita AC, Hamilton EP, Annunziata CM, Grote HJ, von Heydebreck A, Grewal J, et al. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial. Jama Oncology. PMID 30676622 DOI: 10.1001/Jamaoncol.2018.6258 |
0.426 |
|
| 2019 |
Morelli MP, Houston ND, Lipkowitz S, Lee J, Zimmer ADS, Zia FZ, Trewhitt K, Nichols E, Pavelova M, Hewitt SM, Fantini M, Arlen PM, Tsang KY, Annunziata CM. Phase I with expansion cohorts in a study of NEO-201 in adults with chemo-resistant solid tumors. Journal of Clinical Oncology. 37: 129-129. DOI: 10.1200/Jco.2020.38.4_Suppl.129 |
0.323 |
|
| 2019 |
Duemler A, Green DS, Highfill SL, Stroncek D, Zoon K, Annunziata CM. Production of autologous monocytes stimulated ex vivo with peg-interferon alfa 2b and interferon gamma 1b for intraperitoneal administration in phase I clinical trial. Journal of Clinical Oncology. 37: 5-5. DOI: 10.1200/Jco.2019.37.8_Suppl.5 |
0.39 |
|
| 2019 |
Green DS, Johnson CL, Qi C, Tosh KW, Kamenyeva O, Zoon KC, Annunziata CM. Abstract TMIM-073: THE COMBINATION OF INTERFERONS ALPHA AND GAMMA AND MONOCYTES INDUCES OVARIAN CANCER CELL DEATH AND PROVIDE A RATIONALE FOR A NOVEL, ONGOING, IMMUNOTHERAPY PHASE 1 CLINICAL TRIAL Clinical Cancer Research. 25. DOI: 10.1158/1557-3265.Ovcasymp18-Tmim-073 |
0.474 |
|
| 2019 |
Ghobadi A, Thaker P, Weng D, Vanas J, Ekwede I, Pavlova M, Keefe R, Kuo M, Ullmann CD, Hassan R, Annunziata C. Abstract CT159: A phase 1 study of intraperitoneal MCY-M11 therapy for women with platinum resistant high grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube, or subjects with peritoneal mesothelioma with recurrence after prior chemotherapy Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct159 |
0.433 |
|
| 2019 |
Arlen PM, Fantini M, David J, Annunziata CM, Tsang KY, Morelli P. Abstract 3947: Mechanisms of action of a neoantigen-targeting antibody NEO-201 Cancer Research. 79: 3947-3947. DOI: 10.1158/1538-7445.Am2019-3947 |
0.408 |
|
| 2019 |
Annunziata C, Dansky-Ullmann C, Ghobadi A, Weng D, Vanas J, Ekwede I, Pavelova M, Keefe R, Kuo M, Hassan R, Thaker P. A phase I study of intraperitoneal MCY-M11 Anti-mesothelin CAR for women with platinum resistant high grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube, or subjects with peritoneal mesothelioma with recurrence after prior chemotherapy Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz253.133 |
0.366 |
|
| 2018 |
Green DS, Nunes AT, David-Ocampo V, Ekwede IB, Houston ND, Highfill SL, Khuu H, Stroncek DF, Steinberg SM, Zoon KC, Annunziata CM. A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron (Peginterferon alfa-2b) and Actimmune (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer. Journal of Translational Medicine. 16: 196. PMID 30012146 DOI: 10.1186/S12967-018-1569-5 |
0.423 |
|
| 2018 |
Zhang J, Chen T, Yang X, Cheng H, Späth SS, Clavijo PE, Chen J, Silvin C, Issaeva N, Su X, Yarbrough WG, Annunziata CM, Chen Z, Van Waes C. Attenuated TRAF3 fosters alternative activation of NF-κB and reduced expression of anti-viral interferon, TP53, and RB to promote HPV-positive head and neck cancers. Cancer Research. PMID 29921694 DOI: 10.1158/0008-5472.Can-17-0642 |
0.343 |
|
| 2018 |
Weiss JM, Davies LC, Karwan M, Ileva L, Ozaki MK, Cheng RY, Ridnour LA, Annunziata CM, Wink DA, McVicar DW. Itaconic acid mediates crosstalk between macrophage metabolism and peritoneal tumors. The Journal of Clinical Investigation. PMID 29920191 DOI: 10.1172/Jci99169 |
0.323 |
|
| 2018 |
Brooks D, Zimmer A, Wakefield L, Lyle LT, Difilippantonio S, Tucci FC, Illiano S, Annunziata CM, Steeg PS. Limited fibrosis accompanies triple-negative breast cancer metastasis in multiple model systems and is not a preventive target. Oncotarget. 9: 23462-23481. PMID 29805748 DOI: 10.18632/Oncotarget.25231 |
0.352 |
|
| 2018 |
House CD, Grajales V, Ozaki M, Jordan E, Wubneh H, Kimble DC, James JM, Kim MK, Annunziata CM. IΚΚε cooperates with either MEK or non-canonical NF-kB driving growth of triple-negative breast cancer cells in different contexts. Bmc Cancer. 18: 595. PMID 29801480 DOI: 10.1186/S12885-018-4507-2 |
0.377 |
|
| 2018 |
Dull AB, Wilsker D, Hollingshead M, Mazcko C, Annunziata CM, LeBlanc AK, Doroshow JH, Kinders RJ, Parchment RE. Development of a quantitative pharmacodynamic assay for apoptosis in fixed tumor tissue and its application in distinguishing cytotoxic drug-induced DNA double strand breaks from DNA double strand breaks associated with apoptosis. Oncotarget. 9: 17104-17116. PMID 29682208 DOI: 10.18632/Oncotarget.24936 |
0.33 |
|
| 2018 |
Lee JM, Nair J, Zimmer A, Lipkowitz S, Annunziata CM, Merino MJ, Swisher EM, Harrell MI, Trepel JB, Lee MJ, Bagheri MH, Botesteanu DA, Steinberg SM, Minasian L, Ekwede I, et al. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study. The Lancet. Oncology. PMID 29361470 DOI: 10.1016/S1470-2045(18)30009-3 |
0.372 |
|
| 2018 |
Gatti-Mays M, Greer Y, Steinberg S, Soltani S, Collins J, Olson M, Ojemuyiwa M, Annunziata C, Lee J, Nunes A, Lipkowitz S, Zimmer A. Abstract OT2-07-04: A phase 2 study of ONC201 in recurrent/refractory metastatic breast cancer and advanced endometrial carcinoma Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-Ot2-07-04 |
0.405 |
|
| 2018 |
Fantini M, David JM, Wong HC, Annunziata CM, Arlen PM, Tsang KY. Abstract 619: ALT-803 enhances antibody-dependent cell-mediated cytotoxicity (ADCC) mediated by NEO-201 against human carcinoma cells Cancer Research. 78: 619-619. DOI: 10.1158/1538-7445.Am2018-619 |
0.407 |
|
| 2018 |
House CD, Grajales V, Ozaki M, Jordan E, Wubneh H, Kimble D, Kim M, Annunziata CM. Abstract 5470: IKK-epsilon supports anchorage independent growth via alternative NF-kB signaling in triple-negative breast cancer Cancer Research. 78: 5470-5470. DOI: 10.1158/1538-7445.Am2018-5470 |
0.409 |
|
| 2018 |
David JM, Fantini M, Annunziata CM, Arlen PM, Tsang KY. Abstract 3821: The neoantigen-targeting antibody NEO-201 enhances NK cell-dependent killing of tumor cells through blockade of the inhibitory CEACAM5/CEACAM1 immune checkpoint pathway Cancer Research. 78: 3821-3821. DOI: 10.1158/1538-7445.Am2018-3821 |
0.408 |
|
| 2018 |
Ozaki MK, House CD, Mazan-Mamczarz K, Lal-Nag M, Thomas C, Annunziata CM. Abstract 167: Targeting the NF-kappaB pathway with bardoxolone methyl to inhibit ovarian cancer spheroid formation Cancer Research. 78: 167-167. DOI: 10.1158/1538-7445.Am2018-167 |
0.447 |
|
| 2018 |
Lee J, Annunziata C, Houston N, Kohn E, Lipkowitz S, Minasian L, Nichols E, Trepel J, Trewhitt K, Zia F, Zimmer A. A phase II study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa) Annals of Oncology. 29: viii334. DOI: 10.1093/Annonc/Mdy285.145 |
0.32 |
|
| 2018 |
Zeligs KP, Ning F, Hernandez L, Smyth T, Ward G, Annunziata CM. IAP antagonism enhances anti-tumor activity of docetaxel or panobinostat in ovarian cancer cell lines Gynecologic Oncology. 149: 13. DOI: 10.1016/J.Ygyno.2018.04.035 |
0.434 |
|
| 2017 |
Nunes AT, Annunziata CM. Proteasome inhibitors: structure and function. Seminars in Oncology. 44: 377-380. PMID 29935898 DOI: 10.1053/J.Seminoncol.2018.01.004 |
0.324 |
|
| 2017 |
Fantini M, David JM, Saric O, Dubeykovskiy A, Cui Y, Mavroukakis SA, Bristol A, Annunziata CM, Tsang KY, Arlen PM. Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas. Frontiers in Immunology. 8: 1899. PMID 29354121 DOI: 10.3389/Fimmu.2017.01899 |
0.35 |
|
| 2017 |
Annunziata CM, Kohn EC. Clinical trials in gynecologic oncology: Past, present, and future. Gynecologic Oncology. PMID 29212614 DOI: 10.1097/Ogx.0000000000000550 |
0.376 |
|
| 2017 |
Pongas GN, Annunziata CM, Staudt LM. PI3Kδ inhibition causes feedback activation of PI3Kα in the ABC subtype of diffuse large B-cell lymphoma. Oncotarget. 8: 81794-81802. PMID 29137222 DOI: 10.18632/Oncotarget.20864 |
0.395 |
|
| 2017 |
Lee JM, Hays JL, Chiou VL, Annunziata CM, Swisher EM, Harrell MI, Yu M, Gordon N, Sissung TM, Ji J, Figg WD, Minasian L, Lipkowitz S, Wood BJ, Doroshow J, et al. Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer. Oncotarget. 8: 79175-79187. PMID 29108297 DOI: 10.18632/Oncotarget.16577 |
0.373 |
|
| 2017 |
House CD, Jordan E, Hernandez L, Ozaki M, James JM, Kim M, Kruhlak MJ, Batchelor E, Elloumi F, Cam MC, Annunziata CM. NF-kB promotes ovarian tumorigenesis via classical pathways supporting proliferative cancer cells and alternative pathways supporting ALDH+ cancer stem-like cells. Cancer Research. PMID 29074539 DOI: 10.1158/0008-5472.Can-17-0366 |
0.459 |
|
| 2017 |
Pongas G, Kim MK, Min DJ, House CD, Jordan E, Caplen N, Chakka S, Ohiri J, Kruhlak MJ, Annunziata CM. BRD4 facilitates DNA damage response and represses CBX5/Heterochromatin protein 1 (HP1). Oncotarget. 8: 51402-51415. PMID 28881656 DOI: 10.18632/Oncotarget.17572 |
0.388 |
|
| 2017 |
Peer CJ, Lee JM, Roth J, Rodgers L, Nguyen J, Annunziata CM, Minasian L, Kohn EC, Figg WD. Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers. Cancer Chemotherapy and Pharmacology. PMID 28577239 DOI: 10.1007/S00280-017-3346-1 |
0.393 |
|
| 2017 |
Lee JM, Cimino-Mathews A, Peer CJ, Zimmer A, Lipkowitz S, Annunziata CM, Cao L, Harrell MI, Swisher EM, Houston N, Botesteanu DA, Taube JM, Thompson E, Ogurtsova A, Xu H, et al. Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016721340. PMID 28471727 DOI: 10.1200/Jco.2016.72.1340 |
0.338 |
|
| 2017 |
Sanchez-Martin D, Uldrick TS, Kwak H, Ohnuki H, Polizzotto MN, Annunziata CM, Raffeld M, Wyvill KM, Aleman K, Wang V, Marshall VA, Whitby D, Yarchoan R, Tosato G. Evidence for a Mesothelial Origin of Body Cavity Effusion Lymphomas. Journal of the National Cancer Institute. 109. PMID 28376153 DOI: 10.1093/Jnci/Djx016 |
0.343 |
|
| 2017 |
Nunes AT, Green D, Ekwede I, Zoon K, Annunziata CM. Phase 1 study of intraperitoneal infusion of autologous monocytes with peginterferon alfa-2b and interferon gamma-1b in women with recurrent or refractory ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Journal of Clinical Oncology. 35: TPS3092-TPS3092. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps3092 |
0.457 |
|
| 2017 |
Osei-Tutu A, Nunes AT, Lee J, Yu M, Hernandez L, Chen HX, Takebe N, Houston ND, Ekwede I, Steinberg SM, Chen J, Cao L, Figg WD, Butcher D, Annunziata CM, et al. A phase I dose expansion cohort study of dasatinib in combination with bevacizumab in advanced solid tumors (NCT01445509). Journal of Clinical Oncology. 35: 2585-2585. DOI: 10.1200/Jco.2017.35.15_Suppl.2585 |
0.366 |
|
| 2017 |
Walcott FL, Annunziata CM, Sotomayor EM, Fojo AT. Effect of metformin chemoprevention on metabolomics profiles in Li-Fraumeni Syndrome (LFS). Journal of Clinical Oncology. 35: 1556-1556. DOI: 10.1200/Jco.2017.35.15_Suppl.1556 |
0.317 |
|
| 2017 |
Hernandez L, Annunziata CM. Abstract AP26: SMAC–MIMETIC TREATMENT ENHANCES ANTITUMOR EFFECT OF STANDARD CHEMOTHERAPY IN OVARIAN CANCERS EXPRESSING LOW CASPASE 8 IN VITRO AND IN VIVO Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Ovcasymp16-Ap26 |
0.445 |
|
| 2017 |
House CD, Jordan EA, Annunziata CM. Abstract AP13: NF-KAPPAB CLASSICAL VERSUS ALTERNATIVE PATHWAYS SUPPORT DISTINCT POPULATIONS OF OVARIAN CANCER TUMOR-INITIATING CELLS Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Ovcasymp16-Ap13 |
0.473 |
|
| 2017 |
Zeligs K, Arlen PM, Tsang K, Hernandez L, Fantini M, Annunziata CM. Abstract 3025: Preclinical characterization of a novel monoclonal antibody targeting a neo-antigen expressed in ovarian and GI malignancies Cancer Research. 77: 3025-3025. DOI: 10.1158/1538-7445.Am2017-3025 |
0.453 |
|
| 2017 |
House CD, Annunziata CM. Abstract 1910: NF-kappaB classical versus alternative pathways support distinct populations of ovarian cancer tumor-initiating cells Cancer Research. 77: 1910-1910. DOI: 10.1158/1538-7445.Am2017-1910 |
0.424 |
|
| 2017 |
Ozaki MK, House CD, Annunziata CM. Abstract 112: Identifying drugs that target ovarian cancer tumor initiating cells Cancer Research. 77: 112-112. DOI: 10.1158/1538-7445.Am2017-112 |
0.413 |
|
| 2017 |
Zimmer A, Peer C, Cao L, Kohn E, Lipkowitz S, Annunziata C, Trepel J, Lee M, Mikkilineni L, Gatti-Mays M, Nunes A, Soltani S, Figg W, Houston N, Nichols E, et al. A phase I study of durvalumab (D) in combination with olaparib (O) and cediranib (C) in recurrent women’s cancers Annals of Oncology. 28: v130. DOI: 10.1093/Annonc/Mdx367.024 |
0.311 |
|
| 2016 |
Wang PY, Li J, Walcott FL, Kang JG, Starost MF, Talagala SL, Zhuang J, Park JH, Huffstutler RD, Bryla CM, Mai PL, Pollak M, Annunziata CM, Savage SA, Fojo AT, et al. Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome. The Journal of Clinical Investigation. PMID 27869650 DOI: 10.1172/Jci88668 |
0.311 |
|
| 2016 |
Lee JM, Peer CJ, Yu M, Amable L, Gordon N, Annunziata CM, Houston N, Goey AK, Sissung TM, Parker B, Minasian L, Chiou V, Murphy RF, Widemann BC, Figg WD, et al. Sequence-specific pharmacokinetic and pharmacodynamic phase I/Ib study of olaparib tablets and carboplatin in women's cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27663600 DOI: 10.1158/1078-0432.Ccr-16-1546 |
0.336 |
|
| 2016 |
Kim MK, Caplen N, Chakka S, Hernandez L, House C, Pongas G, Jordan E, Annunziata CM. Identification of therapeutic targets applicable to clinical strategies in ovarian cancer. Bmc Cancer. 16: 678. PMID 27558154 DOI: 10.1186/S12885-016-2675-5 |
0.395 |
|
| 2016 |
Eytan DF, Snow GE, Carlson S, Derakhshan A, Saleh A, Schiltz S, Cheng H, Mohan S, Cornelius S, Coupar JF, Sowers AL, Hernandez L, Mitchell JB, Annunziata CM, Chen Z, et al. SMAC mimetic birinapant plus radiation eradicates human head and neck cancers with genomic amplifications of cell death genes FADD and BIRC2. Cancer Research. PMID 27469115 DOI: 10.1158/0008-5472.Can-15-3317 |
0.421 |
|
| 2016 |
Zeligs KP, Neuman MK, Annunziata CM. Molecular Pathways: The Balance between Cancer and the Immune System Challenges the Therapeutic Specificity of Targeting Nuclear Factor-κB Signaling for Cancer Treatment. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27422962 DOI: 10.1158/1078-0432.Ccr-15-1374 |
0.434 |
|
| 2016 |
Hernandez L, Kim MK, Lyle LT, Bunch KP, House CD, Ning F, Noonan AM, Annunziata CM. Characterization of ovarian cancer cell lines as in vivo models for preclinical studies. Gynecologic Oncology. PMID 27235858 DOI: 10.1016/J.Ygyno.2016.05.028 |
0.413 |
|
| 2016 |
Zorn KK, Annunziata CM. Editorial: Inhibiting PARP as a Strategic Target in Cancer. Frontiers in Oncology. 6: 91. PMID 27148483 DOI: 10.3389/Fonc.2016.00091 |
0.379 |
|
| 2016 |
Green DS, Nunes AT, Annunziata CM, Zoon KC. Monocyte and interferon based therapy for the treatment of ovarian cancer. Cytokine & Growth Factor Reviews. PMID 27026228 DOI: 10.1016/J.Cytogfr.2016.02.006 |
0.425 |
|
| 2016 |
Kotlyar D, Greer Y, Voeller D, Hernandez L, Annunziata CM, Lipkowitz S. Effect of the combination of tumor necrosis factor related apoptosis inducing ligand (TRAIL) and the cyclin dependent kinase inhibitor dinaciclib on HPV+ cervical cancer cells. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.E17016 |
0.369 |
|
| 2016 |
Lee J, Zimmer ADS, Lipkowitz S, Annunziata CM, Ho TW, Chiou VL, Minasian LM, Houston ND, Ekwede I, Kohn EC. Phase I study of the PD-L1 inhibitor, durvalumab (MEDI4736; D) in combination with a PARP inhibitor, olaparib (O) or a VEGFR inhibitor, cediranib (C) in women's cancers (NCT02484404). Journal of Clinical Oncology. 34: 3015-3015. DOI: 10.1200/Jco.2016.34.15_Suppl.3015 |
0.365 |
|
| 2016 |
Hernandez L, Kim MK, Lyle LT, Steeg PS, Annunziata CM. Abstract B43: Characterization of ovarian cancer cells as in vivo models for preclinical studies. Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Ovca15-B43 |
0.463 |
|
| 2016 |
House CD, Annunziata CM. Abstract A72: Dissecting the role of NF-kappaB signaling in ovarian cancer tumor-initiating cells. Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Ovca15-A72 |
0.469 |
|
| 2016 |
Walcott FL, Hwang PM, Wang P, Savage SA, Mai P, Steinberg SM, Pollak MN, Annunziata C, Fojo AT. Abstract CT156: Safety and tolerability of metformin for chemoprevention in Li-Fraumeni syndrome (LFS) Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Ct156 |
0.319 |
|
| 2016 |
Kotlyar DS, Greer YE, Voeller D, Hernandez L, Annunziata CM, Lipkowitz S. Abstract 4688: HPV+ cervical cancer cells are selectively killed by the combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and the cyclin-dependent kinase-9 inhibitor (CDK9i) dinaciclib Cancer Research. 76: 4688-4688. DOI: 10.1158/1538-7445.Am2016-4688 |
0.342 |
|
| 2016 |
Derakhshan A, Eytan D, Snow G, Carlson S, Saleh A, Cheng H, Schiltz S, Mohan S, Cornelius S, Coupar J, Sowers A, Hernandez L, Mitchell J, Annunziata C, Chen Z, et al. Abstract 3821: Targeted therapy for head and neck squamous cell carcinoma using the novel SMAC-mimetic birinapant Cancer Research. 76: 3821-3821. DOI: 10.1158/1538-7445.Am2016-3821 |
0.418 |
|
| 2016 |
Goldlust IS, Wilson K, Szabova L, Zhang X, Mathews-Griner L, Vias M, Piskorz A, Stark R, Mendil L, Kasbekar M, Braisted J, Guha R, McKnight C, Shinn P, Michelle-Smith D, ... ... Annunziata C, et al. Abstract 278: No cell left behind: Residual ovarian spheroids drive recurrence and are sensitive to the pro-oxidant elesclomol Cancer Research. 76: 278-278. DOI: 10.1158/1538-7445.Am2016-278 |
0.48 |
|
| 2016 |
Goey AKL, Peer CJ, Sissung TM, Roth J, Shahbazi S, Nguyen J, Annunziata CM, Houston N, Kohn EC, Lee J, Figg WD. Abstract 2043: Effects of 24-h carboplatin pretreatment on olaparib clearance in women's cancers using noncompartmental and population pharmacokinetic analyses Cancer Research. 76: 2043-2043. DOI: 10.1158/1538-7445.Am2016-2043 |
0.385 |
|
| 2016 |
Neuman MK, Hernandez L, Wang X, Saric O, Dubeykovskiy A, Arlen P, Annunziata CM. Abstract 1496: Identification of target and cytotoxicity of novel monoclonal antibody NEO-201 in ovarian and uterine cancer subtypes Cancer Research. 76: 1496-1496. DOI: 10.1158/1538-7445.Am2016-1496 |
0.461 |
|
| 2016 |
Lee J, Karzai F, Zimmer A, Annunziata C, Lipkowitz S, Parker B, Houston N, Ekwede I, Kohn E. A phase II study of the cell cycle checkpoint kinases 1 and 2 inhibitor (LY2606368; Prexasertib monomesylate monohydrate) in sporadic high-grade serous ovarian cancer (HGSOC) and germline BRCA mutation-associated ovarian cancer (gBRCAm+ OvCa) Annals of Oncology. 27: vi296. DOI: 10.1093/Annonc/Mdw374.02 |
0.411 |
|
| 2016 |
Karzai F, Zimmer A, Lipkowitz S, Annunziata C, Parker B, Houston N, Ekwede I, Kohn E, Lee J. A phase II study of the cell cycle checkpoint kinases 1 and 2 (CHK1/2) inhibitor (LY2606368; prexasertib) in sporadic triple negative breast cancer (TNBC) Annals of Oncology. 27: vi71. DOI: 10.1093/Annonc/Mdw365.10 |
0.349 |
|
| 2016 |
Bunch KP, Kim MKH, Zeligs KP, Goldlust IS, Thomas CJ, Annunziata CM. Upregulation of the extrinsic apoptosis pathway by docetaxel, panobinostat, and volasertib may potentiate synergy with birinapant in high-grade serous ovarian cancer Gynecologic Oncology. 141: 163. DOI: 10.1016/J.Ygyno.2016.04.425 |
0.406 |
|
| 2016 |
Neuman MK, Hernandez L, Wang XP, Saric O, Dubeykovskiy A, Arlen P, Annunziata CM. Identification of target and cytotoxicity of novel monoclonal antibody NEO-201 in ovarian and uterine cancer subtypes Gynecologic Oncology. 141: 95-96. DOI: 10.1016/J.Ygyno.2016.04.264 |
0.369 |
|
| 2015 |
Hernandez L, Kim MK, Noonan AM, Sagher E, Kohlhammer H, Wright G, Lyle LT, Steeg PS, Anver M, Bowtell DD, Annunziata CM. A dual role for Caspase8 and NF-κB interactions in regulating apoptosis and necroptosis of ovarian cancer, with correlation to patient survival. Cell Death Discovery. 1: 15053-15053. PMID 28179987 DOI: 10.1038/Cddiscovery.2015.53 |
0.484 |
|
| 2015 |
Noonan AM, Bunch KP, Chen JQ, Herrmann MA, Lee JM, Kohn EC, O'Sullivan CC, Jordan E, Houston N, Takebe N, Kinders RJ, Cao L, Peer CJ, Figg WD, Annunziata CM. Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer. Cancer. PMID 26566079 DOI: 10.1002/Cncr.29783 |
0.427 |
|
| 2015 |
Holkova B, Zingone A, Kmieciak M, Bose P, Badros AZ, Voorhees PM, Baz R, Korde N, Lin HY, Chen JQ, Herrmann MA, Xi L, Raffeld M, Zhao X, Wan W, ... ... Annunziata CM, et al. A Phase 2 Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26446942 DOI: 10.1158/1078-0432.Ccr-15-1076 |
0.33 |
|
| 2015 |
Gharwan H, Bunch KP, Annunziata CM. The role of reproductive hormones in epithelial ovarian carcinogenesis. Endocrine-Related Cancer. 22: R339-63. PMID 26373571 DOI: 10.1530/Erc-14-0550 |
0.394 |
|
| 2015 |
Bunch KP, Annunziata CM. Are beta-blockers on the therapeutic horizon for ovarian cancer treatment? Cancer. 121: 3380-3. PMID 26301564 DOI: 10.1002/Cncr.29394 |
0.329 |
|
| 2015 |
House CD, Wang BD, Ceniccola K, Williams R, Simaan M, Olender J, Patel V, Baptista-Hon DT, Annunziata CM, Silvio Gutkind J, Hales TG, Lee NH. Voltage-gated Na(+) Channel Activity Increases Colon Cancer Transcriptional Activity and Invasion Via Persistent MAPK Signaling. Scientific Reports. 5: 11541. PMID 26096612 DOI: 10.1038/Srep11541 |
0.358 |
|
| 2015 |
Kim MK, James J, Annunziata CM. Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells. Bmc Cancer. 15: 196. PMID 25884494 DOI: 10.1186/S12885-015-1231-Z |
0.451 |
|
| 2015 |
House CD, Hernandez L, Annunziata CM. In vitro enrichment of ovarian cancer tumor-initiating cells. Journal of Visualized Experiments : Jove. PMID 25742116 DOI: 10.3791/52446 |
0.454 |
|
| 2015 |
Hamilton EP, Birrer MJ, DiCarlo BA, Gaillard S, Martin LP, Nemunaitis JJ, Perez RP, Schilder RJ, Annunziata CM, Begley CG, Hager SJ. A phase 1b, open-label, non-randomized multicenter study of birinapant in combination with conatumumab in subjects with relapsed epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. Journal of Clinical Oncology. 33: 5571-5571. DOI: 10.1200/Jco.2015.33.15_Suppl.5571 |
0.403 |
|
| 2015 |
Chiou VL, Kohn EC, Annunziata CM, Minasian LM, Lipkowitz S, Yu M, Gordon N, Houston ND, Lee J. Phase I/Ib study of the PARP inhibitor (PARPi) olaparib (O) with carboplatin (C) in heavily pretreated high-grade serous ovarian cancer (HGSOC) at low genetic risk (NCT01445418). Journal of Clinical Oncology. 33: 5514-5514. DOI: 10.1200/Jco.2015.33.15_Suppl.5514 |
0.302 |
|
| 2015 |
Noonan AM, Hernandez L, Herrmann M, Chen J, Annunziata CM. Abstract POSTER-THER-1422: Development of proteomic biomarkers for the apoptosis pathway in ovarian cancer cell lines and determination of the appropriate sequence of the SMAC-mimetic birinapant (TL32711) and docetaxel for optimal therapeutic effect Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Ovcasymp14-Poster-Ther-1422 |
0.403 |
|
| 2015 |
Hernandez L, Noonan AM, Sagher E, Kohlhammer H, Wright G, Reed LT, Steeg PS, Anver M, Bowtell DD, Annunziata CM. Abstract POSTER-TECH-1102: Caspase 8 cooperates with IKKβ to protect ovarian cancer cells from necroptosis Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Ovcasymp14-Poster-Tech-1102 |
0.494 |
|
| 2015 |
Bunch K, Goldlust I, Thomas C, Hernandez L, Guha R, Annunziata C. Abstract LB-254: High-throughput drug matrix screen with SMAC (second mitochondria-derived activator of caspases)-mimetic birinapant in high-grade serous ovarian cancer cell lines identifies synergism Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-254 |
0.465 |
|
| 2015 |
Chiou VL, Annunziata C, Lipkowitz S, Minasian L, Gordon N, Yu M, Steinberg S, Houston N, Kohn E, Lee J. Abstract CT326: Pharmacokinetic/pharmacodynamic study of sequence specificity of the PARP inhibitor, olaparib and carboplatin in recurrent women's cancers Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Ct326 |
0.369 |
|
| 2015 |
Kim MKH, James J, Annunziata C. Abstract 3490: Topotecan synergizes with CHEK1 inhibitor to induce apoptosis in ovarian cancer cells Cancer Research. 75: 3490-3490. DOI: 10.1158/1538-7445.Am2015-3490 |
0.477 |
|
| 2015 |
House C, Grajales V, Wubneh H, Kimble D, Kim M, Annunziata C. Abstract 1955: IKKε maintains MEK activation and suppresses non-canonical NF-κB signaling in triple-negative breast cancer Cancer Research. 75: 1955-1955. DOI: 10.1158/1538-7445.Am2015-1955 |
0.396 |
|
| 2015 |
Bunch KP, Goldlust IS, Thomas CJ, Annunziata CM. High-throughput matrix screening in ovarian cancer cells identifies synergistic drug combinations with the second mitochondrial-derived activator of caspases (SMAC) mimetic birinapant (TL32711) Gynecologic Oncology. 137: 207-208. DOI: 10.1016/J.Ygyno.2015.01.522 |
0.362 |
|
| 2014 |
Kim MK, Min DJ, Wright G, Goldlust I, Annunziata CM. Loss of compensatory pro-survival and anti-apoptotic modulator, IKKε, sensitizes ovarian cancer cells to CHEK1 loss through an increased level of p21. Oncotarget. 5: 12788-802. PMID 25474241 DOI: 10.18632/Oncotarget.2665 |
0.465 |
|
| 2014 |
Sagher E, Hernandez L, Heywood C, Pauly GT, Young MR, Schneider J, Colburn NH, Annunziata CM. The small molecule NSC676914A is cytotoxic and differentially affects NFκB signaling in ovarian cancer cells and HEK293 cells. Cancer Cell International. 14: 75. PMID 25324692 DOI: 10.1186/S12935-014-0075-Y |
0.449 |
|
| 2014 |
Lee JM, Hays JL, Annunziata CM, Noonan AM, Minasian L, Zujewski JA, Yu M, Gordon N, Ji J, Sissung TM, Figg WD, Azad N, Wood BJ, Doroshow J, Kohn EC. Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. Journal of the National Cancer Institute. 106: dju089. PMID 24842883 DOI: 10.1093/Jnci/Dju089 |
0.393 |
|
| 2014 |
Szabova L, Bupp S, Kamal M, Householder DB, Hernandez L, Schlomer JJ, Baran ML, Yi M, Stephens RM, Annunziata CM, Martin PL, Van Dyke TA, Weaver Ohler Z, Difilippantonio S. Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer. Plos One. 9: e95649. PMID 24748377 DOI: 10.1371/Journal.Pone.0095649 |
0.431 |
|
| 2014 |
House CD, Hernandez L, Annunziata CM. Recent technological advances in using mouse models to study ovarian cancer. Frontiers in Oncology. 4: 26. PMID 24592355 DOI: 10.3389/Fonc.2014.00026 |
0.395 |
|
| 2014 |
Bunch KP, Noonan AM, Lee J, O'Sullivan CCM, Houston ND, Ekwede I, Chen J, Herrmann M, Cao L, Takebe N, Burns J, Weng DE, Kohn EC, Annunziata CM. Pharmacodynamic biomarkers from phase II study of the SMAC (Second Mitochondrial-Derived Activator of Caspases)-mimetic birinapant (TL32711; NSC 756502) in relapsed platinum-resistant epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC) (NCT01681368). Journal of Clinical Oncology. 32: 5585-5585. DOI: 10.1200/Jco.2014.32.15_Suppl.5585 |
0.441 |
|
| 2014 |
Lee J, Annunziata CM, Hays JL, Choyke PL, Cao L, Yu M, Azad NS, Houston ND, Minasian LM, Gordon N, Chen HX, Wright JJ, Kohn EC. A phase II study of intermittent sorafenib with bevacizumab (B) in B-naive and prior B-exposed epithelial ovarian cancer (EOC) patients. Journal of Clinical Oncology. 32: 5553-5553. DOI: 10.1200/Jco.2014.32.15_Suppl.5553 |
0.302 |
|
| 2014 |
Kotlyar D, Petrovas C, Cooper A, Ambrozak D, Annunziata C, Hernandez L, Yamamoto T, Ferrando-Martinez S, Casazza J, Koup R. Potential Synergy of TRAIL with CDK9 Inhibition in Selective Killing of HIV Infected Cell Lines and Primary CD4+ T Cells Blood. 124: 4142-4142. DOI: 10.1182/Blood.V124.21.4142.4142 |
0.356 |
|
| 2014 |
Chiou VL, Kohn EC, Annunziata CM, Minasian L, Zujewski J, Yu M, Ji J, Doroshow J, Gordon N, Houston N, Lee J. Abstract CT337: Phase I/Ib study of the PARP inhibitor (PARPi) olaparib (O) with carboplatin (C) in triple negative breast cancer (TNBC) at low genetic risk (NCT00647062) Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Ct337 |
0.331 |
|
| 2014 |
Kim MKH, Min DJ, Wright G, Annunziata CM. Abstract 5179: Context-specific dependence of ovarian cancer on IKKε and CHEK1 Cancer Research. 74: 5179-5179. DOI: 10.1158/1538-7445.Am2014-5179 |
0.503 |
|
| 2014 |
House CD, Annunziata CM. Abstract 1923: NF-κB signaling supports a sub-population of ovarian cancer tumor-initiating cells Cancer Research. 74: 1923-1923. DOI: 10.1158/1538-7445.Am2014-1923 |
0.483 |
|
| 2013 |
Hays JL, Kim G, Walker A, Annunziata CM, Lee JM, Squires J, Houston N, Steinberg SM, Kohn EC. A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety. Molecular and Clinical Oncology. 1: 565-569. PMID 24649212 DOI: 10.3892/Mco.2013.99 |
0.405 |
|
| 2013 |
Annunziata CM, Kohn EC. Novel facts about FAK: new connections to drug resistance? Journal of the National Cancer Institute. 105: 1430-1. PMID 24062526 DOI: 10.1093/Jnci/Djt255 |
0.4 |
|
| 2013 |
Azad N, Yu M, Davidson B, Choyke P, Chen CC, Wood BJ, Venkatesan A, Henning R, Calvo K, Minasian L, Edelman DC, Meltzer P, Steinberg SM, Annunziata CM, Kohn EC. Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort. Molecular & Cellular Proteomics : McP. 12: 1621-31. PMID 23449826 DOI: 10.1074/Mcp.M112.026427 |
0.364 |
|
| 2013 |
Annunziata CM, Kohn EC, LoRusso P, Houston ND, Coleman RL, Buzoianu M, Robbie G, Lechleider R. Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors. Investigational New Drugs. 31: 77-84. PMID 22370972 DOI: 10.1007/S10637-012-9801-2 |
0.368 |
|
| 2013 |
Lee J, Annunziata CM, Hays JL, Noonan AM, Minasian LM, Zujewski J, Yu M, Ji JJ, Sissung T, Houston ND, Kohn EC. Phase I/Ib study of the PARP inhibitor olaparib (O) with carboplatin (C) in BRCA1/2 mutation carriers with breast or ovarian cancer (Br/OvCa) (NCT00647062). Journal of Clinical Oncology. 31: 2514-2514. DOI: 10.1200/Jco.2013.31.15_Suppl.2514 |
0.302 |
|
| 2013 |
Widemann BC, Reinke DK, Helman LJ, Ludwig JA, Schuetze S, Staddon AP, Milhem MM, Rushing DA, Moertel CL, Goldman S, Livingston MB, Wagner LM, Rodler ET, Dombi E, Perry A, ... Annunziata CM, et al. SARC006: Phase II trial of chemotherapy in sporadic and neurofibromatosis type 1 (NF1)-associated high-grade malignant peripheral nerve sheath tumors (MPNSTs). Journal of Clinical Oncology. 31: 10522-10522. DOI: 10.1200/Jco.2013.31.15_Suppl.10522 |
0.338 |
|
| 2013 |
Lee J, Annunziata C, Noonan AM, Hays JL, Minasian L, Zujewski JA, Chen H, Wright J, Houston N, Kohn EC. Abstract 35: Phase I study of dasatinib in combination with bevacizumab in advanced solid tumors (NCT01445509). Cancer Research. 73: 35-35. DOI: 10.1158/1538-7445.Am2013-35 |
0.363 |
|
| 2013 |
Kim MKH, Wright G, Staudt L, Annunziata C. Abstract 3144: shRNA library screening by dual shRNA technique identifies CHEK1 as a synthetic lethal gene in the absence of IKKε in ovarian cancer. Cancer Research. 73: 3144-3144. DOI: 10.1158/1538-7445.Am2013-3144 |
0.472 |
|
| 2013 |
Noonan AM, Casablanca Y, Maxwell GL, Annunziata CM. Abstract 2007: The NF-kB pathway is constitutively active in endometrial cancer. Cancer Research. 73: 2007-2007. DOI: 10.1158/1538-7445.Am2013-2007 |
0.462 |
|
| 2013 |
Moon DH, Hays JL, Annunziata CM, Noonan AM, Minasian L, Houston N, Kohn EC, Lee J. Abstract 1188: BRCA 1/2 mutation status is correlated with increased hypersensitivity reactions to carboplatin. Cancer Research. 73: 1188-1188. DOI: 10.1158/1538-7445.Am2013-1188 |
0.315 |
|
| 2013 |
Kim MK, Chakka S, Caplen N, Annunziata C. Abstract B25: An unbiased functional screen identifies kinases essential to ovarian cancer cell survival Clinical Cancer Research. 19. DOI: 10.1158/1078-0432.Ovca13-B25 |
0.488 |
|
| 2013 |
Lee J, Hays J, Noonan A, Annunziata C, Minasian L, Zujewski J, Houston N, Hearn J, Yu M, Kohn E. Phase I/Ib study of the PARP inhibitor (PARPi) olaparib (O/AZD2281) in combination with carboplatin (C) in ovarian cancer (OvCa) patients with BRCA1/2 mutations (OvCaMUT+) and high grade serous OvCa (HGSOC) with low genetic risk (NCT00647062) Gynecologic Oncology. 130. DOI: 10.1016/J.Ygyno.2013.04.083 |
0.343 |
|
| 2012 |
Weng MT, Lee JH, Wei SC, Li Q, Shahamatdar S, Hsu D, Schetter AJ, Swatkoski S, Mannan P, Garfield S, Gucek M, Kim MK, Annunziata CM, Creighton CJ, Emanuele MJ, et al. Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 109: E3659-67. PMID 23236152 DOI: 10.1073/Pnas.1207673110 |
0.419 |
|
| 2012 |
Hsu S, Kim M, Hernandez L, Grajales V, Noonan A, Anver M, Davidson B, Annunziata CM. IKK-ε coordinates invasion and metastasis of ovarian cancer. Cancer Research. 72: 5494-504. PMID 22942254 DOI: 10.1158/0008-5472.Can-11-3993 |
0.467 |
|
| 2012 |
Kim G, Davidson B, Henning R, Wang J, Yu M, Annunziata C, Hetland T, Kohn EC. Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome Cancer. 118: 1543-1553. PMID 22009736 DOI: 10.1002/Cncr.26449 |
0.381 |
|
| 2012 |
Driscoll JJ, Burris J, Annunziata CM. Targeting the proteasome with bortezomib in multiple myeloma: update on therapeutic benefit as an upfront single agent, induction regimen for stem-cell transplantation and as maintenance therapy. American Journal of Therapeutics. 19: 133-44. PMID 21248621 DOI: 10.1097/Mjt.0B013E3181Ff7A9E |
0.333 |
|
| 2012 |
Lee J, Hays JL, Noonan AM, Squires J, Annunziata CM, Wood BJ, Yu M, Houston ND, Azad NS, Kohn EC. Feasibility and safety of sequential research-related tumor core biopsies in clinical trials with anti-angiogenic and targeted therapies. Journal of Clinical Oncology. 30: 2545-2545. DOI: 10.1200/Jco.2012.30.15_Suppl.2545 |
0.31 |
|
| 2012 |
Kim MKH, Annunziata C. Abstract LB-421: Dual shRNA technique to screen gene-to-gene interaction Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-421 |
0.378 |
|
| 2012 |
Lee J, Hays J, Annunziata CM, Minasian L, Zujewski J, Squires J, Nielsen D, Houston N, Moorshead D, Cedillo M, Kohn EC. Abstract 1754: A pharmacokinetics/pharmacodynamics study of sequence specificity of the PARP inhibitor, olaparib (O) with carboplatin (C) in recurrent women's cancers NCT01237067 Cancer Research. 72: 1754-1754. DOI: 10.1158/1538-7445.Am2012-1754 |
0.345 |
|
| 2012 |
Hernandez L, Kohlhammer H, Staudt L, Annunziata C. 392 Genome-wide shRNa Library Screen Identifies CASPASE 8 as a Gene Sensitizing Ovarian Cancer Cells to IKKβ Inhibition European Journal of Cancer. 48: 119. DOI: 10.1016/S0959-8049(12)72190-1 |
0.393 |
|
| 2011 |
Kohn EC, Lee J, Annunziata CM, Minasian LM, Zujewski J, Prindiville SA, Kotz HL, Squires J, Houston ND, Chen HX, Wright JJ. A phase II study of intermittent sorafenib with bevacizumab in bevacizumab-naive epithelial ovarian cancer (EOC) patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 5019. PMID 28023762 DOI: 10.1200/Jco.2011.29.15_Suppl.5019 |
0.387 |
|
| 2011 |
Annunziata CM, Hernandez L, Davis RE, Zingone A, Lamy L, Lam LT, Hurt EM, Shaffer AL, Kuehl WM, Staudt LM. A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood. 117: 2396-404. PMID 21163924 DOI: 10.1182/Blood-2010-04-278788 |
0.371 |
|
| 2011 |
Zingone A, Korde N, Chen J, Xi L, Raffeld M, Holkova B, Kmieciak M, Sullivan D, Doyle A, Maric I, Calvo K, Yancey MA, Mulquin M, Annunziata C, Grant S, et al. Molecular Characterization and Clinical Correlations of MEK1/2 Inhibition (AZD6244) in Relapse or Refractory Multiple Myeloma: Analysis From a Phase II Study Blood. 118: 306-306. DOI: 10.1182/Blood.V118.21.306.306 |
0.414 |
|
| 2011 |
Annunziata CM, Hsu S, Hernandez L, Kohn E, Davidson B. Abstract 1479: IKK-epsilon contributes to the malignant progression of ovarian cancer Cancer Research. 71: 1479-1479. DOI: 10.1158/1538-7445.Am2011-1479 |
0.477 |
|
| 2010 |
Annunziata CM, O'Shaughnessy J. Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 4517-26. PMID 20823142 DOI: 10.1158/1078-0432.Ccr-10-0526 |
0.374 |
|
| 2010 |
Annunziata CM, Birrer MJ. CD157 in ovarian carcinoma: how does it help us? Journal of the National Cancer Institute. 102: 1104-5. PMID 20639477 DOI: 10.1093/Jnci/Djq269 |
0.396 |
|
| 2010 |
Annunziata CM, Stavnes HT, Kleinberg L, Berner A, Hernandez LF, Birrer MJ, Steinberg SM, Davidson B, Kohn EC. Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer. Cancer. 116: 3276-84. PMID 20564628 DOI: 10.1002/Cncr.25190 |
0.431 |
|
| 2010 |
Hernandez L, Hsu SC, Davidson B, Birrer MJ, Kohn EC, Annunziata CM. Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer. Cancer Research. 70: 4005-14. PMID 20424119 DOI: 10.1158/0008-5472.Can-09-3912 |
0.456 |
|
| 2010 |
Annunziata CM, Walker AJ, Minasian L, Yu M, Kotz H, Wood BJ, Calvo K, Choyke P, Kimm D, Steinberg SM, Kohn EC. Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2 Clinical Cancer Research. 16: 664-672. PMID 20068097 DOI: 10.1158/1078-0432.Ccr-09-2308 |
0.392 |
|
| 2010 |
Lee JM, Sarosy GA, Annunziata CM, Azad N, Minasian L, Kotz H, Squires J, Houston N, Kohn EC. Combination therapy: Intermittent sorafenib with bevacizumab yields activity and decreased toxicity British Journal of Cancer. 102: 495-499. PMID 20051952 DOI: 10.1038/Sj.Bjc.6605514 |
0.305 |
|
| 2010 |
Driscoll JJ, Pelluru D, Lefkimmiatis K, Fulciniti M, Prabhala RH, Greipp PR, Barlogie B, Tai YT, Anderson KC, Shaughnessy JD, Annunziata CM, Munshi NC. The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. Blood. 115: 2827-34. PMID 19965618 DOI: 10.1182/Blood-2009-03-211045 |
0.381 |
|
| 2010 |
Driscoll JJ, Burris J, Annunziata CM. Novel Strategies in the Treatment of Multiple Myeloma: From Proteasome Inhibitors to Immunotherapy Journal of Cell Science and Therapy. 1: 1-8. DOI: 10.4172/2157-7013.1000101 |
0.4 |
|
| 2010 |
Kim G, Annunziata CM, Sarosy GA, Minasian LM, Prindiville SA, Zujewski J, Otten L, Squires J, Houston ND, Kohn EC. Phase I study of dasatinib in combination with bevacizumab in advanced solid tumors. Journal of Clinical Oncology. 28. DOI: 10.1200/Jco.2010.28.15_Suppl.Tps163 |
0.334 |
|
| 2010 |
Driscoll JJ, Gootenberg J, Amin S, Pelluru D, Avet-loiseau H, Minville S, Anderson KC, Munshi NC, Annunziata CM. Abstract 1978: The poly-SUMO protein specific E3 ubiquitin ligase RNF4 is induced in multiple myeloma and reduces bortezomib-induced cell killing Cancer Research. 70: 1978-1978. DOI: 10.1158/1538-7445.Am10-1978 |
0.423 |
|
| 2009 |
Azad NS, Henning R, Yu M, Davidson B, Figg WD, Calvo K, Venkatasen A, Annunziata C, Meltzer P, Kohn E. Translational proof of mechanism (PoM) for sorafenib with bevacizumab: Endpoint analysis and clinical activity. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3574. PMID 27961719 DOI: 10.1200/Jco.2009.27.15_Suppl.3574 |
0.414 |
|
| 2009 |
Annunziata CM, Kotz HL. Uterine papillary serous carcinoma: a new paradigm for treatment? Cancer. 115: 3594-6. PMID 19452535 DOI: 10.1002/Cncr.24425 |
0.324 |
|
| 2009 |
Hernandez L, Hsu S, Davidson B, Birrer MJ, Kohn EC, Annunziata CM. Abstract C158: IKKβ inhibition modulates NF‐κB signaling and decreases aggressiveness of ovarian cancer Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-C158 |
0.472 |
|
| 2008 |
Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, Minasian L, Sarosy G, Kotz HL, Premkumar A, Cao L, McNally D, Chow C, Chen HX, Wright JJ, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 3709-14. PMID 18669456 DOI: 10.1200/Jco.2007.10.8332 |
0.309 |
|
| 2008 |
Poruchynsky MS, Sackett DL, Robey RW, Ward Y, Annunziata C, Fojo T. Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition. Cell Cycle (Georgetown, Tex.). 7: 940-9. PMID 18414063 DOI: 10.4161/Cc.7.7.5625 |
0.331 |
|
| 2008 |
Azad NS, Annunziata CM, Steinberg SM, Minasian L, Premkumar A, Chow C, Kotz HL, Kohn EC. Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy. Cancer. 112: 1726-32. PMID 18300236 DOI: 10.1002/Cncr.23374 |
0.31 |
|
| 2007 |
Kohn EC, Azad N, Annunziata C, Dhamoon AS, Whiteley G. Proteomics as a tool for biomarker discovery Disease Markers. 23: 411-417. PMID 18057524 DOI: 10.1155/2007/967023 |
0.33 |
|
| 2007 |
Annunziata CM, Kleinberg L, Davidson B, Berner A, Gius D, Tchabo N, Steinberg SM, Kohn EC. BAG-4/SODD and associated antiapoptotic proteins are linked to aggressiveness of epithelial ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 6585-92. PMID 18006758 DOI: 10.1158/1078-0432.Ccr-07-0327 |
0.383 |
|
| 2007 |
Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, Dave S, Hurt EM, Tan B, Zhao H, Stephens O, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 12: 115-30. PMID 17692804 DOI: 10.1016/J.Ccr.2007.07.004 |
0.384 |
|
| 2007 |
Azad NS, Annunziata C, Barrett T, Chen C, Steinberg S, Kwitkowski VE, McNally D, Kotz H, Minasian L, Kohn EC. Dual targeting of vascular endothelial growth factor (VEGF) with sorafenib and bevacizumab: Clinical and translational results Journal of Clinical Oncology. 25: 3542-3542. DOI: 10.1200/Jco.2007.25.18_Suppl.3542 |
0.309 |
|
| 2006 |
Azad NS, Rasool N, Annunziata CM, Minasian L, Whiteley G, Kohn EC. Proteomics in clinical trials and practice: present uses and future promise. Molecular & Cellular Proteomics : McP. 5: 1819-29. PMID 16737951 DOI: 10.1074/Mcp.R600008-Mcp200 |
0.31 |
|
| 2006 |
Azad NS, Posadas EM, Kwitkowski VE, Annunziata CM, Barrett T, Premkumar A, Kotz HL, Sarosy GA, Minasian LM, Kohn EC. Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab Journal of Clinical Oncology. 24: 3004-3004. DOI: 10.1200/Jco.2006.24.18_Suppl.3004 |
0.329 |
|
| 2003 |
Annunziata CM, Kohn EC. Is there a genomic basis for primary chemoresistance in ovarian cancer? Gynecologic Oncology. 90: 1-2. PMID 12821333 DOI: 10.1016/S0090-8258(03)00315-9 |
0.358 |
|
| 2000 |
Annunziata CM, Safiran YJ, Irving SG, Kasid UN, Cossman J. Hodgkin disease: pharmacologic intervention of the CD40-NF kappa B pathway by a protease inhibitor. Blood. 96: 2841-8. PMID 11023520 |
0.694 |
|
| 2000 |
Annunziata CM, Safiran YJ, Irving SG, Kasid UN, Cossman J. Hodgkin disease: pharmacologic intervention of the CD40-NFκB pathway by a protease inhibitor Blood. 96: 2841-2848. DOI: 10.1182/Blood.V96.8.2841.H8002841_2841_2848 |
0.735 |
|
| 1999 |
Cossman J, Annunziata CM, Barash S, Staudt L, Dillon P, He WW, Ricciardi-Castagnoli P, Rosen CA, Carter KC. Reed-Sternberg cell genome expression supports a B-cell lineage. Blood. 94: 411-6. PMID 10397707 |
0.716 |
|
| 1999 |
Cossman J, Annunziata CM, Barash S, Staudt L, Dillon P, He W, Ricciardi-Castagnoli P, Rosen CA, Carter KC. Reed-Sternberg Cell Genome Expression Supports a B-Cell Lineage Blood. 94: 411-416. DOI: 10.1182/Blood.V94.2.411.414K47_411_416 |
0.726 |
|
| Show low-probability matches. |